ZEALAND PHARMA A/S (22Z.DE) Stock Price, Forecast & Analysis
FRA:22Z • DK0060257814
22Z.DE Key Statistics, Chart & Performance
The current stock price of 22Z.DE is 52.6 EUR. In the past month the price decreased by -3.91%.
22Z.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 22Z.DE.
22Z.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 22Z.DE. While 22Z.DE has a great health rating, its profitability is only average at the moment.
22Z.DE Financial Highlights
Over the last trailing twelve months 22Z.DE reported a non-GAAP Earnings per Share(EPS) of 12.45. The EPS increased by 661.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 71.47% | ||
| ROA | 38.95% | ||
| ROE | 43.15% | ||
| Debt/Equity | 0.03 |
22Z.DE Forecast & Estimates
24 analysts have analysed 22Z.DE and the average price target is 96.27 EUR. This implies a price increase of 83.02% is expected in the next year compared to the current price of 52.6.
For the next year, analysts expect an EPS growth of 670.67% and a revenue growth 11460.5% for 22Z.DE
22Z.DE Ownership
22Z.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.32 | 44.408B | ||
| 1AE | ARGENX SE | 28.26 | 44.383B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.99B | ||
| 2X1 | ABIVAX SA | N/A | 8.714B | ||
| ABVX | ABIVAX SA | N/A | 8.698B | ||
| GLPG | GALAPAGOS NV | N/A | 1.902B | ||
| GXE | GALAPAGOS NV | N/A | 1.897B | ||
| IVA | INVENTIVA SA | N/A | 1.153B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| NANO | NANOBIOTIX | N/A | 1.079B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 22Z.DE
Company Profile
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Company Info
ZEALAND PHARMA A/S
Sydmarken 11
Soeborg DK
Employees: 335
Phone: 4588773600
ZEALAND PHARMA A/S / 22Z.DE FAQ
What does ZEALAND PHARMA A/S do?
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
What is the current price of 22Z stock?
The current stock price of 22Z.DE is 52.6 EUR. The price decreased by -2.45% in the last trading session.
What is the dividend status of ZEALAND PHARMA A/S?
22Z.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of 22Z stock?
22Z.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is ZEALAND PHARMA A/S (22Z.DE) stock traded?
22Z.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is the market capitalization of 22Z stock?
ZEALAND PHARMA A/S (22Z.DE) has a market capitalization of 2.43B EUR. This makes 22Z.DE a Mid Cap stock.